Fennec Pharmaceuticals (FRX) Hits New 12-Month Low at $5.97

Fennec Pharmaceuticals Inc (TSE:FRX) hit a new 52-week low on Monday . The company traded as low as C$5.97 and last traded at C$6.16, with a volume of 6290 shares changing hands. The stock had previously closed at C$6.50.

The firm has a market cap of $123.55 million and a PE ratio of -11.90.

Fennec Pharmaceuticals (TSE:FRX) last announced its quarterly earnings results on Wednesday, March 13th. The biopharmaceutical company reported C($0.20) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of C($0.18) by C($0.02).

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Markets Daily and is owned by of Markets Daily. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.themarketsdaily.com/2019/04/17/fennec-pharmaceuticals-frx-hits-new-12-month-low-at-5-97.html.

Fennec Pharmaceuticals Company Profile (TSE:FRX)

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.

Further Reading: How a Put Option Works

Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.